Stock Talk Podcast Episode 124

This week, on the precipice of a historic U.S. election I will start with a brief commentary on making portfolio decisions based on election outcomes. Back by popular demand we have decided to make our new Case For, Case Against segment a permanent fixture. Our head of income research, Mr. Aaron Dunn will make his highly anticipated first argument facing off against Brennan. In the line of fire is Apple Inc. (AAPL: NASDAQ), the iPhone company which should need no introduction. While the stock sold off this week after its quarterly results included a lack of forward guidance, the consumer tech giant is up 47% this year. We argue both sides of the BUY/SELL argument for the stock. With a hat tip to Movember and men’s cancer prevention and treatment, this week’s Your Stock, Our Take was sent in from a listener on Profound Medical Corp. (PRN: TSX), a medical technology company developing medical treatments with its core technology used to ablate the prostate gland. We let you know if the share price gains are justifiable based on the underlying cash flow at present.